PL356001A1 - Zastosowanie antagonistów receptorów beta-adrenergicznych do wytwarzania leku do leczenia zaburzeń zewnętrznej siatkówki - Google Patents

Zastosowanie antagonistów receptorów beta-adrenergicznych do wytwarzania leku do leczenia zaburzeń zewnętrznej siatkówki

Info

Publication number
PL356001A1
PL356001A1 PL00356001A PL35600100A PL356001A1 PL 356001 A1 PL356001 A1 PL 356001A1 PL 00356001 A PL00356001 A PL 00356001A PL 35600100 A PL35600100 A PL 35600100A PL 356001 A1 PL356001 A1 PL 356001A1
Authority
PL
Poland
Prior art keywords
disorders
medicament
beta
manufacture
treatment
Prior art date
Application number
PL00356001A
Other languages
English (en)
Other versions
PL214875B1 (pl
Inventor
Robert J.Jr. Collier
Michael A. Kapin
Louis Desantis Jr.
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Publication of PL356001A1 publication Critical patent/PL356001A1/pl
Publication of PL214875B1 publication Critical patent/PL214875B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL356001A 1999-11-30 2000-11-29 Zastosowanie antagonistów receptorów ß-adrenergicznych do wytwarzania leku do leczenia zaburzen zewnetrznej siatkówki PL214875B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16799399P 1999-11-30 1999-11-30
PCT/US2000/032575 WO2001043737A1 (en) 1999-11-30 2000-11-29 Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina

Publications (2)

Publication Number Publication Date
PL356001A1 true PL356001A1 (pl) 2004-05-31
PL214875B1 PL214875B1 (pl) 2013-09-30

Family

ID=22609644

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356001A PL214875B1 (pl) 1999-11-30 2000-11-29 Zastosowanie antagonistów receptorów ß-adrenergicznych do wytwarzania leku do leczenia zaburzen zewnetrznej siatkówki

Country Status (18)

Country Link
US (4) US7081482B2 (pl)
EP (1) EP1244438B1 (pl)
JP (2) JP4758581B2 (pl)
CN (1) CN1245966C (pl)
AT (1) ATE253905T1 (pl)
AU (1) AU782524B2 (pl)
BR (1) BR0015938A (pl)
CA (1) CA2388728C (pl)
DE (1) DE60006584T2 (pl)
DK (1) DK1244438T3 (pl)
ES (1) ES2210023T3 (pl)
HK (1) HK1047695B (pl)
MX (1) MXPA02005378A (pl)
PL (1) PL214875B1 (pl)
PT (1) PT1244438E (pl)
TR (1) TR200302008T4 (pl)
WO (1) WO2001043737A1 (pl)
ZA (1) ZA200203133B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1244438B1 (en) * 1999-11-30 2003-11-12 Alcon, Inc. Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
CN100413503C (zh) * 2005-01-07 2008-08-27 冷文 一种复方眼药组合物
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
CA2717825A1 (en) * 2008-03-07 2009-09-11 Sun Pharma Advanced Research Company Ltd. Opthalmic composition
US10267796B2 (en) * 2010-10-25 2019-04-23 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
MX2019012476A (es) * 2017-04-21 2020-02-12 Hoffman Steven Composiciones y metodos para tratar la retinopatia.
EP3787749A4 (en) * 2018-05-03 2022-01-26 Alimera Sciences, Inc. METHODS OF TREATMENT OF RETINAL DISEASES
JP7392219B2 (ja) * 2020-01-20 2023-12-06 株式会社萌芽プランツ フラボノイド組成物
US20230248671A1 (en) * 2020-07-10 2023-08-10 Chang Gung Memorial Hospital, Linkou Use of beta-1 adrenergic receptor antagonist for preparing compositions for reducing epithelial cell damage induced by epidermal growth factor receptor inhibitors and inhibiting cancer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2330383A1 (fr) 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US4443432A (en) 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
US6066675A (en) 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
BR9913955A (pt) * 1998-09-25 2001-06-12 Alcon Lab Inc Composição oftalmológica confortável e de liberação sustentada e método para terapia ocular
EP1244438B1 (en) 1999-11-30 2003-11-12 Alcon, Inc. Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina

Also Published As

Publication number Publication date
US20060199868A1 (en) 2006-09-07
EP1244438B1 (en) 2003-11-12
ES2210023T3 (es) 2004-07-01
HK1047695B (en) 2004-08-20
JP2010215667A (ja) 2010-09-30
MXPA02005378A (es) 2005-02-25
JP4758581B2 (ja) 2011-08-31
US7081482B2 (en) 2006-07-25
DE60006584T2 (de) 2004-09-30
DE60006584D1 (de) 2003-12-18
CN1402634A (zh) 2003-03-12
JP2003516963A (ja) 2003-05-20
AU782524B2 (en) 2005-08-04
CA2388728C (en) 2009-05-19
HK1047695A1 (en) 2003-03-07
PT1244438E (pt) 2004-02-27
US20020193373A1 (en) 2002-12-19
PL214875B1 (pl) 2013-09-30
TR200302008T4 (tr) 2004-01-21
CN1245966C (zh) 2006-03-22
US8710102B2 (en) 2014-04-29
ATE253905T1 (de) 2003-11-15
US20100249134A1 (en) 2010-09-30
EP1244438A1 (en) 2002-10-02
BR0015938A (pt) 2002-08-27
DK1244438T3 (da) 2004-02-23
WO2001043737A1 (en) 2001-06-21
US20080103211A1 (en) 2008-05-01
AU2052701A (en) 2001-06-25
ZA200203133B (en) 2003-04-22
CA2388728A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
AU2604301A (en) Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
ZA200003236B (en) Combination therapy for the treatment of migraine.
EP1440689A3 (en) Treatment of neurotic disorders
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
PL356001A1 (pl) Zastosowanie antagonistów receptorów beta-adrenergicznych do wytwarzania leku do leczenia zaburzeń zewnętrznej siatkówki
CA2347863A1 (en) Treatment of disorders of the outer retina
GB0020504D0 (en) Therapeutic method
ZA200107143B (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders.
IL147188A (en) Use of il6ril6 chimera in the manufacture of a remedy for neurological diseases
WO2000061125A3 (fr) L'osanetant dans le traitement des troubles de l'humeur
ZA200003235B (en) Combination therapy for the treatment of migraine.
ZA200002338B (en) Combination therapy for the treatment of migraine.
SI1458376T1 (sl) Darifenacin za uporabo pri zdravljenju nuje, ki je posledica prekomerno aktivnega sečnega mehurja
ZA200002343B (en) Combination therapy for the treatment of migraine.
SI1061940T1 (en) Use of follistatin for the manufacture of a medicament for the treatment of muscle-related disorders
WO2000067733A3 (de) Medikament zur therapie der männlichen infertilität
HK1037131A (en) Treatment of disorders of the outer retina
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
HK1029038A (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo

Legal Events

Date Code Title Description
RECP Rectifications of patent specification